Peptides are derived from animal source and possess antibacterial activity that comes under animal antibacterial peptides. They contain residue of amino acids generally about 15 to 45. Antibacterial peptides are the effector molecules of innate immunity. Majority of the antibacterial peptides are cationic in nature. In insects, the cecropin type of linear peptide without cysteine are found. Now, more than 900 sequences of proteins and antibacterial peptides from plants and animals are stored in database. The antibacterial peptides are broad spectrum in activity. The antibacterial peptides are amphipathic in structure and contains positive charge.
The use of low levels of antibiotics in animal feed as growth promoters and rise in use of antibiotics in animal and human infections are causes of antibiotics resistance among gram negative, gram positive, and bacterial pathogens. The natural and synthetics antibacterial peptides are good candidates for antibiotics alternatives. The natural antibiotics are rich source of proteins as well as amino acids and have less side effects as compared to synthetic antibiotics. They possess synergistic activity with conventional antibiotics and promote wound healing. Domestic animals are good source of antibacterial peptides. The antibacterial peptides are expressed in many polymorphonuclear leukocytes, tissues, macrophages, and mucosal epithelial cells. Antibacterial peptides are preserved in their function, structure, and mechanisms of action. Thus, it is attractive to speculate that synthetic antibacterial peptides or their congeners might be used to prevent or treat infections. Antimicrobial peptides are good applicants for the design of new antimicrobial agents for specific application because of their low propensity for the development of bacterial resistance and natural antimicrobial properties. The major driving factor of antibacterial peptides is their ability to kill multi drug resistance bacteria.
The market of animal antibacterial peptide is segmented on the basis of peptide type, product origin, and geography. On the basis of peptide type, the animal antibacterial peptide market is segmented as linear cationic α-helical peptides, anionic peptides, cationic peptide containing specific amino acid, and anionic & cationic peptides that possess cysteine and form disulfide bonds. Anionic peptides are rich in glutamic and aspartic acids whereas cationic peptides are rich in arginine, phenylalanine, glycine, tryptophan, and proline. These peptides are good candidates for supplements to conventional antibiotic therapy and for development as novel therapeutic agents. These are broad spectrum in nature and possess bactericidal activity. Insect’s peptides are one of the largest groups of antimicrobial peptides. Cecropins constitute the most important host defense system against bacterial infection. By product origin, the animal antibacterial peptide market is segmented into cattle origin, sheep origin, goat origin, pig origin, horse origin, and poultry. The animal antibacterial peptides are derived from above sources.
By geography, the market for animal antibacterial peptide is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market. The rise in research is the key driving factor of the animal antibacterial peptide market in North America. Asia pacific is the most progressive region for the animal antibacterial peptide market. The rise in expenditure on animal health care is a key factor responsible for growth of the market. The increasing resistance to conventional antibiotics is likely to be the key driver of the animal antibacterial peptide market during the forecast period. Furthermore, the rise in use of antibiotics to treat various infections and disease in animal feed is projected to fuel the growth of the animal antibacterial peptide market during the forecast period.
Major players operating in the animal antibacterial peptide market include Zoetis, Merck Animal Health, Merial, Elanco (Eli Lilly and Company), Bayer HealthCare, Animal Medics, Biogenesis Bago, and Boehringer Ingelheim Vetmedica. The rising demand for alternatives for conventional antibiotics is estimated to increase the competition between market players of animal antibacterial peptide.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.